fcγr

BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.

Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Ofatumumab is a humanized monoclonal antibody targeting CD20. Ofatumumab acts on CD20-expressing B lymphocytes, inducing antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Anti-Fc gamma R1 Antibody is a humanized monoclonal antibody that targets Fc gamma RI (CD64) and can be used in immunological research.

Anti-CD32/FcγRIIA Antibody (IV.3) is a mouse inhibitory antibody that specifically targets human CD32/FcγRIIA and effectively blocks the function of the FcγRIIA receptor. It is commonly used in research on mechanisms related to inflammation and infection, including models of arthritis and Escherichia coli infection.

(±)-Haloxyfop (Haloxyfop Acid) is a herbicide.

hIgG-hFc receptor-IN-1 is a human immunoglobulin G - human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction inhibitor (IC50: 2 μM).

Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized bispecific antibody targeting FcRH5/CD3. It binds to FcRH5 expressed on multiple myeloma (MM) cells and CD3 on T cells, promoting T cell synapse formation and inhibiting B-cell malignancies.

F-CRI1, a potent STING agonist with a dissociation constant (K d) of 40.62 nM, is an 18F-labeled radioactive probe employed for visualizing STING in the tumor microenvironment [1].

Talizumab (TNX 901) is a humanized IgG1 monoclonal antibody that specifically targets circulating immunoglobulin E (IgE). it binds to free IgE not already bound by the high-affinity IgE receptors (FcεRI) present on mast cells and basophils, which leads to the marked downregulation of these receptors and additionally inhibits allergen-specific T-cell activation by interfering with antigen processing and presentation activities.

Transferrin aldifitox (TF-CRM107), a conjugate of diphtheria toxin CRM107 with transferrin, can be used for anticancer research [1].

Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an IgG1 antibody inhibitor derived from mice, specifically targeting rat FcRn heavy chain heterodimers.

Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is a mouse-derived antibody, specifically targeting the FcRn heavy chain heterodimers. The isotype control for Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is designated as MouseIgG1kappa, Isotype Control.

Anti-FcRH5 Antibody (MFRF3266A, DFRF4539A Naked Antibody) is a highly specific monoclonal antibody targeting FcRH5 (also known as IRTA2 or CD307e) and serves as the antibody backbone for the ADC DFRF4539A (RG-7598), which is used in research related to relapsed or refractory multiple myeloma.

Rilzabrutinib (PRN1008) is a reversible covalent, selective, and orally active inhibitor of Bruton's Tyrosine Kinase (BTK) with an IC50 of 1.3 nM.

BTK-IN-11 is a potent BTK inhibitor with potential applications in research on autoimmune diseases, inflammatory diseases, and cancer.

Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells.

Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor designed as a decoy or scavenger to target Fc and FcγR, binding and neutralizing pathogenic IgG. Its utility lies in mitigating autoimmune diseases, with a particular focus on systemic lupus erythematosus (SLE) research [1].

PKC-ε Translocation Inhibitor Peptide is a selective modulator that controls the FcγR-mediated internalization rate of opsonized beads without affecting FcαR trafficking [1].